The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies
Authors:
- 28 December 2011
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 91 (2) , 281-288
Abstract
We analyzed the cost-effectiveness of the International Conference on Harmonisation (ICH) E14 guideline that requires a thorough QT/QTc (TQT) study for all drugs under development. We compared two pharmacoeconomic scenarios: the health effects and costs resulting from implementing ICH E14 ("regulation" scenario) vs. not implementing ICH E14 ("no regulation" scenario). We used a dynamic population model to calculate the cost-effectiveness of ICH E14 for a prototype QT-prolonging antipsychotic drug entering the US and European markets. The incremental cost-effectiveness ratios of regulation vs. no regulation were ~€2.4 million per sudden cardiac death prevented and ~€187,000 per quality-adjusted life year (QALY) gained in users of antipsychotic drugs. The main driver of cost was the requirement for electrocardiogram (ECG) monitoring of users of QTc-prolonging drugs. Even when several of the assumptions in the model were varied, there were no results in favor of regulation. Our study shows that cost-effectiveness analysis of drug regulatory measures is feasible and should be considered before developing such measures.Keywords
This publication has 31 references indexed in Scilit:
- The social value of a QALY: raising the bar or barring the raise?BMC Health Services Research, 2011
- All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort studyBMC Psychiatry, 2010
- Survival of people with clinical diagnosis of dementia in primary care: cohort studyBMJ, 2010
- Psychometric properties of the EQ-5D in a study of people with mild to moderate dementiaQuality of Life Research, 2010
- Unintended consequences of reducing QT-alert overload in a computerized physician order entry systemEuropean Journal of Clinical Pharmacology, 2009
- Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac DeathNew England Journal of Medicine, 2009
- Cardiac Repolarisation and Drug RegulationDrug Safety, 2007
- Atypical AntipsychoticsDrug Safety, 2005
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- The regulation of the UK pharmaceutical industry: A cost‐benefit analysisManagerial and Decision Economics, 1982